Abstract: A disease animal model, characterized in that a chronic pain is induced by applying a treatment for reducing the biogenic amine level to a mammal, and a method for screening for a therapeutic agent for a chronic pain, characterized in that a test substance is administered to said disease animal model.

Abstract: An agent for treating fibromyalgia containing a 5-HT2C receptor agonist as an active ingredient

Abstract: The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.

Abstract: A disease animal model, characterized in that a chronic pain is induced by applying a treatment for reducing the biogenic amine level to a mammal, and a method for screening for a therapeutic agent for a chronic pain, characterized in that a test substance is administered to said disease animal model.

Abstract: The piperidine derivative of the present invention in which the 4-position of the piperidine ring is bonded, via vinylene, to a mono-substituted (—R1) or unsubstituted benzene ring and the 1-position of the piperidine ring has an acyl group [—C(?O)—R4], or a pharmaceutically acceptable salt thereof has an excellent sodium channel inhibition action and an excellent analgesic action and shows a high analgesic effect particularly to neurogenic pain.

Abstract: The present inventors have carried out intensive screening of a new type compound which inhibits the P2X2/3,3 receptor and found as a result that minodronic acid as a bisphosphonate having bone resorption inhibitory action shows excellent P2X2/3,3 receptor inhibitory action and can be used as a preventive or therapeutic agent for various pains, thus accomplishing the invention. That is, the invention relates to a P2X2/3,3 receptor inhibitor, particularly an analgesic, which comprises minodronic acid or a salt thereof as the active ingredient. Since the “P2X2/3 and/or P2X3 receptor inhibitor” of the invention inhibits the function of P2X2/3,3 receptor known as a molecule which is concerned in various pains consisting of nociceptive pain, inflammatory pain and neurogenic pain, it is useful for the prevention or treatment of various pains in which the P2X2/3,3 receptor is concerned in the pain transduction.

Abstract: The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.

Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.

Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.